Have a feature idea you'd love to see implemented? Let us know!

GLSI Greenwich LifeSciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GLSI

Price (delayed)

$12.97

Market cap

$170.49M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.8

Enterprise value

$164.66M

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a ...

Highlights
The quick ratio has plunged by 78% YoY but it is up by 29% from the previous quarter
The equity fell by 44% YoY and by 15% QoQ
The net income has contracted by 17% YoY and by 2.7% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://greenwichlifesciences.com
Peers: NVAX NVCR NBIX

Key stats

What are the main financial stats of GLSI
Market
Shares outstanding
13.14M
Market cap
$170.49M
Enterprise value
$164.66M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
34.22
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$10.5M
EBITDA
-$10.49M
Free cash flow
-$7.57M
Per share
EPS
-$0.8
Free cash flow per share
-$0.58
Book value per share
$0.38
Revenue per share
$0
TBVPS
$0.44
Balance sheet
Total assets
$5.83M
Total liabilities
$842,384
Debt
$0
Equity
$4.98M
Working capital
$4.98M
Liquidity
Debt to equity
0
Current ratio
6.91
Quick ratio
6.91
Net debt/EBITDA
0.55
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-164.3%
Return on equity
-185.1%
Return on invested capital
N/A
Return on capital employed
-210.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GLSI stock price

How has the Greenwich LifeSciences stock price performed over time
Intraday
0.93%
1 week
-4.56%
1 month
-3.14%
1 year
22.36%
YTD
23.29%
QTD
-9.74%

Financial performance

How have Greenwich LifeSciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$10.76M
Net income
-$10.5M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 17% YoY and by 2.7% from the previous quarter
The operating income has declined by 15% year-on-year and by 2.1% since the previous quarter

Growth

What is Greenwich LifeSciences's growth rate over time

Valuation

What is Greenwich LifeSciences stock price valuation
P/E
N/A
P/B
34.22
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
GLSI's EPS is down by 13% year-on-year
GLSI's P/B is 82% higher than its 5-year quarterly average of 18.8 but 6% lower than its last 4 quarters average of 36.5
The equity fell by 44% YoY and by 15% QoQ

Efficiency

How efficient is Greenwich LifeSciences business performance
The return on equity has dropped by 130% year-on-year and by 20% since the previous quarter
The ROA has shrunk by 109% YoY and by 16% QoQ

Dividends

What is GLSI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GLSI.

Financial health

How did Greenwich LifeSciences financials performed over time
The company's total liabilities has surged by 183% YoY but it fell by 38% QoQ
The quick ratio has plunged by 78% YoY but it is up by 29% from the previous quarter
The company's debt is 100% lower than its equity
The equity fell by 44% YoY and by 15% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.